Barrier Therapeutics, Inc., a pharmaceutical company that develops and markets dermatology products, today announced positive results from its completed Phase 2 dose-finding study of Oral Rambazole in moderate to severe psoriasis. The Company has selected the 2 mg dose for further development based on a statistically significant positive dose response trend for the PASI 75 assessment. A PASI 75 ...
From: biz.yahoo.com
Barrier Therapeutics Announces Positive Phase 2 Data With Oral Rambazole in Moderate to Severe Psoriasis
Posted by Ruslan Abuzant at 5:02 AM
Subscribe to:
Post Comments (Atom)
0 comments:
Post a Comment